Alexa Canchola

Dr. Alexa Canchola

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Open access
WCWei‐Chun Chou
Wei‐Chun Chou
ACAlexa Canchola
Alexa Canchola
FZFan Zhang
Fan Zhang
Zhoumeng LinZhoumeng Lin
Zhoumeng Lin
Nanomedicine harnesses nanoscale materials, such as lipid, polymeric, and inorganic nanoparticles, to deliver diagnostic or therapeutic agents for cancer, infectious disease, and neurological disorders, among others. However, translating promising nanoparticle designs into clinically approved products remains a challenge. Factors such as particle size, surface chemistry, and payload interactions must be optimized, and preclinical results often fail to predict human efficacy. In recent years, artificial intelligence (AI) and machine learning (ML) have emerged as transformative tools to address these hurdles at every stage of nanomedicine development. By rapidly screening extensive libraries and extracting structure–function relationships, AI‐driven models can rationalize nanoparticle formulation, predict biodistribution, and guide optimal design. Techniques like high‐throughput DNA barcoding and automated liquid handling facilitate robust, large‐scale data collection, feeding into computational pipelines that expedite discovery while reducing reliance on resource‐intensive trial‐and‐error experiments. AI‐based platforms also enable improved modeling of protein corona formation, which profoundly affects nanoparticle immunogenicity and cellular uptake. Despite these advances, challenges persist in data standardization, model generalizability, and establishing a clear regulatory framework since no dedicated U.S. Food and Drug Administration (FDA) guidance addresses the intersection of AI and nanomedicine. Overcoming these limitations requires harmonized data sharing, rigorous in vivo validation, and clear ethical and regulatory guidelines. This review summarizes the rapidly evolving landscape of AI in nanomedicine, highlighting key successes in design and preclinical prediction, as well as persistent obstacles to full‐scale clinical integration. By illuminating these dynamics, we aim to chart a more efficient path forward in developing next‐generation nanomedicine.

22 September 2019 in Atmosphere
Verified
Journal Article
Open access
PDF file
Huanhuan JiangHuanhuan Jiang
Huanhuan Jiang
CAC M SABBIR Ahmed
C M SABBIR Ahmed
ACAlexa Canchola
Alexa Canchola
JCJin Ya Chen
Jin Ya Chen
YLYing-Hsuan Lin
Ying-Hsuan Lin
Oxidative potential (OP) has been proposed as a useful descriptor for the ability of particulate matter (PM) to generate reactive oxygen species (ROS) and consequently induce oxidative stress in biological systems, which has been recognized as one of the most important mechanisms responsible for PM toxicity. The dithiothreitol (DTT) assay is one of the most frequently used techniques to quantify OP because it is low-cost, easy-to-operate, and has high repeatability. With two thiol groups, DTT has been used as a surrogate of biological sulfurs that can be oxidized when exposed to ROS. Within the DTT measurement matrix, OP is defined as the DTT consumption rate. Often, the DTT consumption can be attributed to the presence of transition metals and quinones in PM as they can catalyze the oxidation of DTT through catalytic redox reactions. However, the DTT consumption by non-catalytic PM components has not been fully investigated. In addition, weak correlations between DTT consumption, ROS generation, and cellular responses have been observed in several studies, which also reveal the knowledge gaps between DTT-based OP measurements and their implication on health effects. In this review, we critically assessed the current challenges and limitations of DTT measurement, highlighted the understudied DTT consumption mechanisms, elaborated the necessity to understand both PM-bound and PM-induced ROS, and concluded with research needs to bridge the existing knowledge gaps.

1 October 2025 in ACS Nano
Verified
Journal Article
Open access
ACAlexa Canchola
Alexa Canchola
KLKeyuan Li
Keyuan Li
KCKunpeng Chen
Kunpeng Chen
ABAlejandro Borboa-Pimentel
Alejandro Borboa-Pimentel
CCCatherine Chou
Catherine Chou
Wei-Chun ChouWei-Chun Chou
Wei-Chun Chou
A comprehensive understanding of protein corona (PC) composition is critical for engineering nanoparticles (NPs) with optimal safety and therapeutic performance, because the PC governs NP pharmacokinetics, biodistribution, and cellular interactions. Yet systematic analyses are hampered by the absence of standardized, richly annotated data sets. Here, we introduce the Protein Corona Database (PC-DB), which compiles data from 83 studies (2000-2024) and integrates 817 NP formulations with quantitative profiles of 2497 adsorbed proteins. The PC-DB exposes pronounced heterogeneity in NP materials (metal 28.8%, silica 22.8%, lipid-based 14.8%), surface modifications, sizes (1-1400 nm), and ζ-potentials (-70 to +70 mV). Subsequent meta-analysis shows that silica, polystyrene, and lipid-based NPs smaller than 100 nm with moderately negative to neutral ζ-potentials preferentially bind the lipoproteins APOE and APOB-100, which are linked to receptor-mediated uptake and enhanced delivery efficiency. In contrast, metal and metal-oxide NPs carrying highly negative surface charge enrich complement component C3, indicating a greater likelihood of immune recognition and clearance. Interpretable machine learning models (LightGBM and XGBoost; ROC-AUC > 0.85) confirm NP size, ζ-potential, and incubation time as the most influential predictors of protein adsorption. These results delineate how physicochemical parameters dictate PC composition and illustrate the power of predictive modeling to guide rational NP design.

9 December 2021 in Toxics
Verified
Journal Article
Open access
PDF file
JCJin Ya Chen
Jin Ya Chen
ACAlexa Canchola
Alexa Canchola
YLYing-Hsuan Lin
Ying-Hsuan Lin
It has been demonstrated that propylene glycol (PG), vegetable glycerin (VG), and flavoring chemicals can thermally degrade to form carbonyls during vaping, but less is known about carbonyl emissions produced by transformation of flavoring chemicals and the interactive effects among e-liquid constituents. This study characterized carbonyl composition and levels in vaping emissions of PG-VG (e-liquid base solvents) and four e-liquid formulations flavored with trans-2-hexenol, benzyl alcohol, l-(-)-menthol, or linalool. Utilizing gas chromatography (GC)- and liquid chromatography (LC)-mass spectrometry (MS) methods, 14 carbonyls were identified and quantified. PG-VG emitted highest levels of formaldehyde, acetaldehyde, and acrolein. However, flavored e-liquids contributed to the production of a wider variety of carbonyls, with some carbonyls directly corresponding to the oxidation of alcohol moieties in flavoring compounds (e.g., trans-2-hexenol and benzyl alcohol transformed into trans-2-hexenal and benzaldehyde, respectively). Detections of formaldehyde-GSH and trans-2-hexenal-GSH adducts signify interactions of carbonyls with biological nucleophiles. The global reactivity descriptors (I, A, μ, η, and ω) and condensed Fukui parameters (fk0, fk−, fk+, and dual-descriptor) were computed to elucidate site reactivities of selected simple and α,β-unsaturated carbonyls found in vaping emissions. Overall, this study highlights carbonyl emissions and reactivities and their potential health risk effects associated with vaping.

1 August 2020 in Environmental Pollution
Verified
Journal Article
Closed access
HJHuanhuan Jiang
Huanhuan Jiang
CAC.M. Sabbir Ahmed
C.M. Sabbir Ahmed
ZZZixu Zhao
Zixu Zhao
JCJin Y. Chen
Jin Y. Chen
HZHaofei Zhang
Haofei Zhang
YLYing-Hsuan Lin
Ying-Hsuan Lin

25 January 2022 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
ACAlexa Canchola
Alexa Canchola
CAC M SABBIR Ahmed
C M SABBIR Ahmed
KCKunpeng Chen
Kunpeng Chen
JCJin Ya Chen
Jin Ya Chen
YLYing-Hsuan Lin
Ying-Hsuan Lin